Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Japan OB/GYN Market Projected at 100 Billion Yen in FY2026: Fuji Keizai
November 9, 2023
- CSL Launches Original Home Delivery Service for Hizentra
November 8, 2023
- Upsher-Smith’s Livalo Generic Hits US Market: Sawai
November 8, 2023
- Eisai CEO Confident of Achieving Leqembi Sales Goal of 10 Billion Yen in FY2023
November 8, 2023
- Keytruda Snares Title in Japan Sales Ranking in October: Encise
November 8, 2023
- 180 Employees Apply for Santen’s Voluntary Buyout Program
November 8, 2023
- Eisai’s H1 Operating Profit Spikes on Lenvima Growth, Divestment Gain
November 8, 2023
- Air Pollutant Might Be to Blame for NDMA Formation in Metformin: Towa Paper
November 7, 2023
- Izervay Slows Geographic Atrophy Lesion Growth through 2 Years: Astellas
November 7, 2023
- Nobelpharma Seeks Provisional Disposition against Sawai’s Nobelzin Copy
November 7, 2023
- Chugai Offloading Xeloda to Cheplapharm after German Firm Plants Flag in Japan
November 7, 2023
- BMS Seeks to Block Sawai’s Sprycel Generic over CML Use
November 7, 2023
- Xocova Claims 1st Trophy in August GP Promotion, Dayvigo Makes Comeback in HP List
November 6, 2023
- Kazunari Tsunaba Steps Down as CEO of Aculys Pharma
November 6, 2023
- Ono Posts Record High H1 Earnings for 6th Consecutive Year Driven by Opdivo
November 2, 2023
- Shionogi, Apnimed to Launch Joint Venture to Develop Sleep Apnea Drugs
November 2, 2023
- Astellas Squeaks Out Sales Rise as FX, Mainstay Growth Offset Generic Hit
November 2, 2023
- Mitsubishi Tanabe’s April-September Sales Up 8% on Radicava
November 2, 2023
- Kyowa Kirin Drops Acoalan’s Preeclampsia Program after PIII Miss
November 2, 2023
- Otsuka Ups 2023 Full-Year Sales Forecast on Bullish Global Brands
November 2, 2023
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…